Scarica l'app Stockscreener
7.677
1.16%
-0.093
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
Cullinan Therapeutics Inc. Stock Analysis and ForecastExceptional stock performance - Jammu Links News
Is Cullinan Therapeutics Inc. a good long term investmentConsistently superior profits - Jammu Links News
What drives Cullinan Therapeutics Inc. stock priceMassive wealth growth - Jammu Links News
What analysts say about Cullinan Therapeutics Inc. stockExceptional portfolio growth - Jammu Links News
Zipalertinib's NDA Submission: Can Cullinan Therapeutics Finally Cash In on Its Breakthrough? - AInvest
Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst - Seeking Alpha
How Cullinan Therapeutics Inc. stock performs during market volatilityChart Breakout Alert - Newser
Why Cullinan Therapeutics Inc. stock attracts strong analyst attentionTop Growth Low Risk Stocks - Newser
What makes Cullinan Therapeutics Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser
Disc Medicine Appoints Nadim Ahmed To Board - citybiz
Disc Medicine Appoints Nadim Ahmed to its Board of Directors - The Manila Times
Disc Medicine, Inc. Appoints Nadim Ahmed to Its Board of Directors - MarketScreener
We're Keeping An Eye On Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Rate - Yahoo Finance
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Cullinan Oncology stock rating reiterated at Buy by Clear Street - Investing.com Australia
Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell Microcap Growth Index - MarketScreener
Assenagon Asset Management S.A. Cuts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld MedTech
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $30.00 - Defense World
Cullinan Management Holds Annual Stockholders Meeting - TipRanks
Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset - BioWorld MedTech
California State Teachers Retirement System Lowers Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Now Covered by Analysts at Stifel Nicolaus - Defense World
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating a - GuruFocus
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating and $22 Price Target | CGEM Stock News - GuruFocus
Stifel Recommends Buy Rating for Cullinan Therapeutics (CGEM) | CGEM Stock News - GuruFocus
Two Sigma Investments LP Has $514,000 Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Squarepoint Ops LLC Sells 11,673 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
The week in pharma: action, reaction and insight – week to June 6 - The Pharma Letter
Two Sigma Advisers LP Grows Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio - Contract Pharma
Cullinan pens $700M pact for BCMA bispecific to pair with another autoimmune T-cell engager - Fierce Biotech
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix - MENAFN.com
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix By Stocktwits - Investing.com India
Transcript : Cullinan Therapeutics, Inc.Special Call - MarketScreener
Cullinan expands autoimmune focus with new T cell engager license By Investing.com - Investing.com South Africa
Cullinan (CGEM) Secures Global Rights for Velinotamig from Genri - GuruFocus
Cullinan Therapeutics (CGEM) Secures Exclusive License for Velin - GuruFocus
Cullinan expands autoimmune focus with new T cell engager license - Investing.com Australia
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical - GuruFocus
Cullinan Therapeutics (CGEM) Secures Exclusive License for Velinotamig Development | CGEM Stock News - GuruFocus
Cullinan Management Enters Global License Agreement with Genrix - TipRanks
Cullinan in pact for multiple myeloma drug (CGEM:NASDAQ) - Seeking Alpha
Cullinan Therapeutics Licenses Rights to Velinotamig - marketscreener.com
Cullinan Therapeutics Licenses Rights to Velinotamig, a - GlobeNewswire
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific ... - Eagle-Tribune
Bank of America Corp DE Cuts Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Nuveen Asset Management LLC - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Decline in Short Interest - Defense World
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - BioSpace
0.86%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):